Laboratory Corporation of America Holdings | Date: 2016-08-22
Methods are provided for a sensitive and specific assay for the determination of viral load and genotyping of RSV in a biological sample. Compositions and kits for use in the methods also are provided, including optimized primers for the amplification of and detection of the RSV open reading frames from subtypes A and B, and probes for distinguishing between the subtypes. Also provided are methods for amplifying and sequencing an open reading from of an RSV F protein, and compositions and kits for use in the methods.
Laboratory Corporation of America Holdings | Date: 2016-06-15
Methods are provided for determining or otherwise assessing the response of a patient to treatment, in particular, to cancer treatment. The methods include the analysis of samples for the presence or the absence of HER2 markers alone or in conjunction with other biomarkers, such as HER3 markers. In certain examples, the probable time to progression can be determined by first determining HER2 positive patients and then further stratifying by using the presence or the absence of a second biomarker (e.g, HER3 markers). In addition, the data can be used to track a patients response to a treatment regimen, assessing the expected success of treating a patient using a particular regiment, determining the effects of a treatment regiment or for categorizing a patient in order to create a homogenous group for a clinical trial.
Laboratory Corporation of America Holdings | Date: 2017-03-01
The invention generally relates to compositions and methods for diagnosing autism spectrum disorders. In certain embodiments, the invention provides a method for diagnosing presence or increased risk of developing an autism spectrum disorder in a subject.
Laboratory Corporation of America Holdings | Date: 2017-02-01
The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.
Laboratory Corporation of America Holdings | Date: 2016-12-28
Disclosed herein are methods and systems for rapid detection of microorganisms in a sample, without culturing for enrichment of the microorganism. A modified bacteriophage is also disclosed which comprises a non-native indicator gene in the late gene region. The indicator product is not a fusion protein. The specificity of infectious agents allows a specific microorganism to be targeted, and an indicator signal may be amplified to optimize assay sensitivity.
Laboratory Corporation of America Holdings | Date: 2017-02-17
The present invention provides methods and compositions for determining whether a subject would benefit from co-receptor inhibitor therapy. In certain aspects, the methods can be used to determine whether a subject infected with a dual-mixed tropic population of HIV would benefit from CCCR5-inhibitor therapy or CXCR4-inhibitor therapy, the methods comprising determining whether the HIV population is a homogeneous or heterogeneous population of HIV, wherein the nature of the homogenous or heterogenous population of HIV indicates whether the patient would benefit from co-receptor inhibitor therapy.
Laboratory Corporation of America Holdings | Date: 2017-03-09
A method of diagnosing bacterial vaginosis in a woman, which involves determining an amount of each of more than one BV-associated bacterium in a vaginal sample obtained from the female and assessing a BV status of the female based on the amount of each of the more than one BV-associated bacterium in the sample.
Laboratory Corporation of America Holdings | Date: 2017-04-12
In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.
Laboratory Corporation of America Holdings | Date: 2016-02-10
Methods and compositions for the efficient and accurate determination of susceptibility of a hepatitis C virus (HCV) or HCV population to an HCV inhibitor. The inhibitor may include, for example, an interferon (IFN), ribavirin (RBV), one or more nucleos(t)ide inhibitors, including for example nucleoside inhibitor-1 (NI-1), 2C-methyl adenosine (2CMeA), sofosbuvir (SOF), or non-nucleoside inhibitor targeting site A or B (NNI-A or NNI-B) are provided. The methods may involve determining the genotype of the HCV or the phenotype of the HCV with respect to the inhibitor susceptibility. The methods may further include the selection of a suitable treatment based on the genotype or phenotype determined.
Laboratory Corporation of America Holdings | Date: 2016-03-03
Disclosed are methods and systems for measuring serotonin in a sample using liquid chromatography and mass spectrometry.